nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

11.12.2015 | Original Paper

Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer’s disease

verfasst von: Fábio B. Mury, Weber C. da Silva, Nádia R. Barbosa, Camila T. Mendes, Juliana S. Bonini, Jorge Eduardo Souza Sarkis, Martin Cammarota, Ivan Izquierdo, Wagner F. Gattaz, Emmanuel Dias-Neto

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Phospholipase A2 (Pla2) is required for memory retrieval, and its inhibition in the hippocampus has been reported to impair memory acquisition in rats. Moreover, cognitive decline and memory deficits showed to be reduced in animal models after lithium treatment, prompting us to evaluate possible links between Pla2, lithium and memory. Here, we evaluated the possible modulation of Pla2 activity by a long-term treatment of rats with low doses of lithium and its impact in memory. Wistar rats were trained for the inhibitory avoidance task, treated with lithium for 100 days and tested for perdurability of long-term memory. Hippocampal samples were used for quantifying the expression of 19 brain-expressed Pla2 genes and for evaluating the enzymatic activity of Pla2 using group-specific radio-enzymatic assays. Our data pointed to a significant perdurability of long-term memory, which correlated with increased transcriptional and enzymatic activities of certain members of the Pla2 family (iPla2 and sPla2) after the chronic lithium treatment. Our data suggest new possible targets of lithium, add more information on its pharmacological activity and reinforce the possible use of low doses of lithium for the treatment of neurodegenerative conditions such as the Alzheimer’s disease.

Nur mit Berechtigung zugänglich

Cade JF (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust 2:349–352PubMed

Manji HK, Moore GJ, Chen G (2000) Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 48:740–754CrossRefPubMed

Shulman KI, Rochon P, Sykora K, Anderson G et al (2003) Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ 326:960–961CrossRefPubMedPubMedCentral

Young AH, Newham JI (2006) Lithium in maintenance therapy for bipolar disorder. J Psychopharmacol 20:17–22CrossRefPubMed

Baldessarini RJ (2002) Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 16:721–729CrossRefPubMed

Manji HK, Moore GJ, Chen G (1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46:929–940CrossRefPubMed

De Strooper B, Woodgett J (2003) Alzheimer’s disease: mental plaque removal. Nature 423:392–393CrossRefPubMed

Gould TD, Chen G, Manji HK (2004) In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacol 29:32–38CrossRef

Mendes CT, Mury FB, de Sa-Moreira E, Alberto FL et al (2009) Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease. Eur Arch Psychiatry Clin Neurosci 259:16–22CrossRefPubMed

10.

Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides. Nature 423:435–439CrossRefPubMed

11.

Li PP, Young LT, Tam YK, Sibony D, Warsh JJ (1993) Effects of chronic lithium and carbamazepine treatment on G-protein subunit expression in rat cerebral cortex. Biol Psychiatry 34:162–170CrossRefPubMed

12.

Manji HK, Potter WZ, Lenox RH (1995) Signal transduction pathways. Molecular targets for lithium’s actions. Arch Gen Psychiatry 52:531–543CrossRefPubMed

13.

Lenox RH, Hahn CG (2000) Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 61:5–15PubMed

14.

Jope RS (1999) Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 4:117–128CrossRefPubMed

15.

Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN (2008) Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience 151:1184–1197CrossRefPubMed

16.

Chen HM, De Long CJ, Bame M, Rajapakse I, Herron TJ, McInnis MG, O’Shea KS (2014) Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients. Transl Psychiatry 4:e375CrossRefPubMedPubMedCentral

17.

Pachet AK, Wisniewski AM (2003) The effects of lithium on cognition: an updated review. Psychopharmacology 170:225–234CrossRefPubMed

18.

Rockenstein E, Torrance M, Adame A, Mante M et al (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3 beta signaling pathway in a transgenic model of Alzheimer’s disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27:1981–1991CrossRefPubMed

19.

Yan XB, Hou HL, Wu LM, Liu J, Zhou JN (2007) Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia. Neuropharmacol 53:487–495CrossRef

20.

Tsaltas E, Kontis D, Boulougouris V, Papakosta VM et al (2007) Enhancing effects of chronic lithium on memory in the rat. Behav Brain Res 177:51–60CrossRefPubMed

21.

Nocjar C, Hammonds MD, Shim SS (2007) Chronic lithium treatment magnifies learning in rats. Neuroscience 150:774–788CrossRefPubMed

22.

Schaeffer EL, Cerulli FG, Souza HO, Catanozi S, Gattaz WF (2014) Synergistic and additive effects of enriched environment and lithium on the generation of new cells in adult mouse hippocampus. J Neural Transm 121:695–706CrossRefPubMed

23.

Su Y, Ryder J, Li B, Wu X et al (2004) Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43:6899–6908CrossRefPubMed

24.

Kusumo KS, Vaughan M (1977) Effects of lithium salts on memory. Br J Psychiatry 131:453–457CrossRefPubMed

25.

Lund Y, Nissen M, Rafaelsen OJ (1982) Long-term lithium treatment and psychological functions. Acta Psychiatr Scand 65:233–244CrossRefPubMed

26.

Squire LR, Judd LL, Janowsky DS, Huey LY (1980) Effects of lithium carbonate on memory and other cognitive functions. Am J Psychiatry 137:1042–1046CrossRefPubMed

27.

van Gorp WG, Altshuler L, Theberge DC, Wilkins J, Dixon W (1998) Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gen Psychiatry 55:41–46CrossRefPubMed

28.

Calil HM, Zwicker AP, Klepacz S (1990) The effects of lithium carbonate on healthy volunteers: mood stabilization? Biol Psychiatry 27:711–722CrossRefPubMed

29.

Weingartner H, Rudorfer MV, Linnoila M (1985) Cognitive effects of lithium treatment in normal volunteers. Psychopharmacology 86:472–474CrossRefPubMed

30.

Nunes PV, Forlenza OV, Gattaz WF (2007) Lithium and risk for Alzheimer’s disease in elderly patients with bipolar disorder. Br J Psychiatry 190:359–360CrossRefPubMed

31.

Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment, randomised controlled trial. Br J Psychiatry 198:351–356CrossRefPubMed

32.

Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L (2014) Mild cognitive impairment: a concept in evolution. J Intern Med 275:214–228CrossRefPubMedPubMedCentral

33.

Bauer M, Alda M, Priller J, Young LT (2003) Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36:S250–S254CrossRefPubMed

34.

Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000) Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75:1729–1734CrossRefPubMed

35.

Dixon JF, Hokin LE (1998) Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc Natl Acad Sci USA 95:8363–8368CrossRefPubMedPubMedCentral

36.

Son H, Yu IT, Hwang SJ, Kim JS et al (2003) Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem 85:872–881CrossRefPubMed

37.

Watase K, Gatchel JR, Sun Y, Emamian E et al (2007) Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med 4:836–847CrossRef

38.

Gattaz WF, Maras A, Cairns NJ, Levy R, Forstl H (1995) Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry 37:13–17CrossRefPubMed

39.

Gattaz WF, Cairns NJ, Levy R, Forstl H, Braus DF, Maras A (1996) Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 246:129–131CrossRefPubMed

40.

Gattaz WF, Levy R, Cairns NJ, Forstl H, Braus DF, Maras A (1996) Relevance of metabolism of membrane phospholipids for Alzheimer dementia. Fortschr Neurol Psychiatr 64:8–12CrossRefPubMed

41.

Schaeffer EL, Gattaz WF (2007) Requirement of hippocampal phospholipase A2 activity for long-term memory retrieval in rats. J Neural Transm 114:379–385CrossRefPubMed

42.

Smesny S, Stein S, Willhardt I, Lasch J, Sauer H (2008) Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia. J Neural Transm 115:1173–1179CrossRefPubMed

43.

Talib LL, Yassuda MS, Diniz BS, Forlenza OV, Gattaz WF (2008) Cognitive training increases platelet PLA2 activity in healthy elderly subjects. Prostaglandins Leukot Essent Fatty Acids 78:265–269CrossRefPubMed

44.

Olfert ED (1993) Guide to the care and use of experimental animals, 2nd edn. Canadian Council on Animal Care, Ottawa

45.

Bernabeu R, Bevilaqua L, Ardenghi P, Bromberg E et al (1997) Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats. Proc Natl Acad Sci USA 94:7041–7046CrossRefPubMedPubMedCentral

46.

Izquierdo LA, Barros DM, Medina JH, Izquierdo I (2003) Exposure to novelty enhances retrieval of very remote memory in rats. Neurobiol Learn Mem 79:51–56CrossRefPubMed

47.

Da Silva WC, Bonini JS, Bevilaqua LRM, Izquierdo I, Cammarota M (2006) Histamine enhances inhibitory avoidance memory consolidation through a H2 receptor-dependent mechanism. Neurobiol Learn Mem 86:100–106CrossRefPubMed

48.

Izquierdo LA, Barros DM, Vianna MR, Coitinho A et al (2002) Molecular pharmacological dissection of short- and long-term memory. Cell Mol Neurobiol 22:269–287CrossRefPubMed

49.

Barros DM, Izquierdo LA, e Souza TM, Ardenghi PG et al (2000) Molecular signalling pathways in the cerebral cortex are required for retrieval of one-trial avoidance learning in rats. Behav Brain Res 114:183–192CrossRefPubMed

50.

Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167CrossRefPubMed

51.

Chomczynsky P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159

52.

Bustin SA, Benes V, Garson JA, Hellemans J et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611–622CrossRefPubMed

53.

Vandesompele J, De Preter K, Pattyn F, Poppe B et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:1–12CrossRef

54.

Forlenza OV, Schaeffer EL, Gattaz WF (2002) Phospholipase A2 activity in rat embryonic brain and in primary cultures of cortical neurons. J Neural Transm 109:623–631CrossRefPubMed

55.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMed

56.

Farooqui AA, Horrocks LA (2004) Brain phospholipases A2, a perspective on the history. Prostaglandins Leukot Essent Fatty Acids 71:161–169CrossRefPubMed

57.

Farooqui AA, Yang HC, Horrocks L (1997) Involvement of phospholipase A2 in neurodegeneration. Neurochem Int 30:517–522CrossRefPubMed

58.

Flesch I, Schmidt B, Ferber E (1985) Acyl chain specificity and kinetic properties of phospholipase A1 and A2 of bone marrow-derived macrophages. Z Naturforsch C 40:356–363PubMed

59.

Noponen M, Sanfilipo M, Samanich K, Ryer H et al (1993) Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 34:641–649CrossRefPubMed

60.

Ross BM, Moszczynska A, Erlich J, Kish SJ (1998) Phospholipid-metabolizing enzymes in Alzheimer’s disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem 70:786–793CrossRefPubMed

61.

Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96:8745–8750CrossRefPubMedPubMedCentral

62.

Frame S, Cohen P (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359:1–16CrossRefPubMedPubMedCentral

63.

Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem. 104:1433–1439CrossRefPubMedPubMedCentral

64.

Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, Du Y, Doody RS, Le W (2011) Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer’s disease transgenic mouse model. J Alzheimer’s Dis 24:739–749

65.

Kessing LV, Forman JL, Andersen PK (2010) Does lithium protect against dementia? Bipolar Disord 12:87–94CrossRefPubMed

66.

Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF (2012) Does lithium prevent Alzheimer’s disease? Drugs Aging 29:335–342CrossRefPubMed

67.

Aprahamian I, Santos FS, Dos Santos B, Talib L, Diniz BS, Radanovic M, Gattaz WF, Forlenza OV (2014) Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry 75:e672–e678CrossRefPubMed

68.

de Sousa RT, Zanetti MV, Busatto GF, Mouro MG, Zarate CA Jr, Gattaz WF, Higa EM, Machado-Vieira R (2014) Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. J Psychiatr Res 55:96–100CrossRefPubMedPubMedCentral

69.

Talbot K, Young RA, Jolly-Tornetta C, Lee VM, Trojanowski JQ, Wolf BA (2000) A frontal variant of Alzheimer’s disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochem Int 37:17–31CrossRefPubMed

70.

Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM (2004) Platelet phospholipase A(2) activity in Alzheimer’s disease and mild cognitive impairment. J Neural Transm 111:591–601CrossRefPubMed

71.

Smith LA, Cornelius V, Warnock A, Bell A, Young AH (2007) Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 9:394–412CrossRefPubMed

72.

Chuang DM (2004) Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 16:83–90CrossRefPubMed

73.

Gattaz WF, Talib LL, Schaeffer EL, Diniz BS, Forlenza OV (2014) Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease, a 4-year follow-up study. J Neural Transm 121:193–200CrossRefPubMed

74.

Schmitt C, Furet Y, Perrotin D, Paintaud G (2009) Acute lithium intoxications, review of the literature and cases study. Therapie 64:55–63CrossRefPubMed

75.

Chuang DM (2005) The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 1053:195–204CrossRefPubMed

76.

Whitlock JR, Heynen AJ, Shuler MG, Bear MF (2006) Learning induces long-term potentiation in the hippocampus. Science 313:1093–1097CrossRefPubMed

77.

Schaeffer EL, Gattaz WF (2005) Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology 181:392–400CrossRefPubMed

78.

Schaeffer EL, Bassi F Jr, Gattaz WF (2005) Inhibition of phospholipase A2 activity reduces membrane fluidity in rat hippocampus. J Neurotransm 112:641–647

79.

Rosenberger TA, Villacreses NE, Contreras MA, Bonventre JV, Rapoport SI (2003) Brain lipid metabolism in the cPLA2 knockout mouse. J Lipid Res 44:109–117CrossRefPubMed

80.

Fujita S, Ikegaya Y, Nishikawa M, Nishiyama N, Matsuki N (2001) Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase A(2) inhibitor in rat hippocampal slices. Br J Pharmacol 132:1417–1422CrossRefPubMedPubMedCentral

81.

Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31–39CrossRefPubMed

82.

Nishizaki T, Nomura T, Matsuoka T, Tsujishita Y (1999) Arachidonic acid as a messenger for the expression of long-term potentiation. Biochem Biophys Res Commun 254:446–449CrossRefPubMed

83.

Schaeffer EL, Forlenza OV, Gattaz WF (2009) Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology 202:37–51CrossRefPubMed

84.

Gama MA, Raposo NR, Mury FB, Lopes FC, Dias-Neto E, Talib LL, Gattaz WF (2015) Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue. J Neural Transm 122:1371–1380CrossRefPubMed

85.

Vakhapova V, Cohen T, Richter Y, Herzog Y, Kam Y, Korczyn AD (2014) Phosphatidylserine containing omega-3 Fatty acids may improve memory abilities in nondemented elderly individuals with memory complaints: results from an open-label extension study. Dement Geriatr Cogn Disord 38:39–45CrossRefPubMed

86.

Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56:159–164CrossRefPubMed

87.

Eckert GP, Schaeffer EL, Schmitt A, Maras A, Gattaz WF (2011) Increased brain membrane fluidity in schizophrenia. Pharmacopsychiatry 44:161–162CrossRefPubMed

88.

Barbosa NR, Junqueira RM, Vallada HP, Gattaz WF (2007) Association between BanI genotype and increased phospholipase A2 activity in schizophrenia. Eur Arch Psychiatry Clin Neurosci 257:340–343CrossRefPubMed

89.

Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF (2003) Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res 61:1–6CrossRefPubMed

90.

Gattaz WF, Schmitt A, Maras A (1995) Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 16:1–6CrossRefPubMed

91.

Ting C, Rajji TK, Ismail Z, Tang-Wai DF, Apanasiewicz N, Miranda D, Mamo D, Mulsant BH (2010) Differentiating the cognitive profile of schizophrenia from that of Alzheimer disease and depression in late life. Plos One 5:e10151CrossRefPubMedPubMedCentral

Titel: Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer’s disease
verfasst von: Fábio B. Mury
Weber C. da Silva
Nádia R. Barbosa
Camila T. Mendes
Juliana S. Bonini
Jorge Eduardo Souza Sarkis
Martin Cammarota
Ivan Izquierdo
Wagner F. Gattaz
Emmanuel Dias-Neto
Publikationsdatum: 11.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 7/2016
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-015-0665-2

Neu im Fachgebiet Psychiatrie

23.04.2024 | Demenz | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Lithium activates brain phospholipase A2 and improves memory in rats: implications for Alzheimer’s disease

Abstract

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2016

Searching biomarkers for mental disorders—lessons from Alzheimer’s disease

Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer’s disease

Restricted attention to social cues in schizophrenia patients

Using the cognitive assessment interview to screen cognitive impairment in psychosis

Mapping CSF biomarker profiles onto NIA–AA guidelines for Alzheimer’s disease

Problem solving, impulse control and planning in patients with early- and late-stage Huntington’s disease

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Psychiatrie